Saturday 4 January 2014
MAPK pathway activation
- BRAF fusions define a new molecular subset of melanoma, potentially comprising 4% to 8% of "pan-negative" cases.
- Their presence may explain an unexpected clinical response to MEK inhibitor therapy or assist in selecting patients for MEK-directed therapy.
BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. Clin Cancer Res. 2013 Dec 15;19(24):6696-702. doi : 10.1158/1078-0432.CCR-13-1746 PMID: 24345920